Can a patient taking apixaban (Eliquis) safely start apalutamide for prostate cancer?

Can a Patient on Apixaban (Eliquis) Safely Start Apalutamide?

Yes, a patient taking apixaban can safely start apalutamide for prostate cancer, but dose adjustment of apixaban is required because apalutamide is a strong CYP3A4 inducer that will significantly reduce apixaban levels, potentially leading to loss of anticoagulant effect and increased thrombotic risk.

Critical Drug Interaction

Apalutamide is a potent inducer of CYP3A4 and P-glycoprotein (P-gp), the same metabolic pathways that eliminate apixaban. While the Eliquis FDA label specifically addresses inhibitors of these pathways (requiring dose reduction) 1, it does not provide guidance on inducers like apalutamide, which have the opposite effect—they accelerate apixaban metabolism and lower drug levels.

The Clinical Evidence

The SPARTAN and TITAN trials specifically allowed concomitant oral anticoagulant use, including apixaban, with apalutamide 2. In the post-hoc analysis:

• SPARTAN study: Among patients receiving concurrent anticoagulants, thrombotic/embolic events occurred in 11.6% (apalutamide + ADT) vs 12.5% (placebo + ADT)
• TITAN study: Events occurred in 19.4% (apalutamide + ADT) vs 21.4% (placebo + ADT)
• Grade 3/4 thrombotic events were comparable between groups
• The analysis concluded that concomitant oral anticoagulants can be used with apalutamide with appropriate monitoring 2

Practical Management Algorithm

Step 1: Assess the indication for anticoagulation

• If for VTE treatment in cancer: Consider switching to LMWH (enoxaparin, dalteparin), which is preferred in cancer-associated thrombosis and not affected by CYP3A4/P-gp induction 3
• If for atrial fibrillation: Proceed with modified approach below

Step 2: If continuing apixaban is necessary:

• Do not reduce the apixaban dose—the standard dosing should be maintained or potentially increased, though no specific guidance exists
• Implement intensive clinical monitoring for signs of thromboembolism
• Consider checking anti-Xa levels if available (though not routinely done)
• Watch for new onset atrial fibrillation symptoms, stroke symptoms, or DVT/PE signs

Step 3: Alternative anticoagulation strategies:

• Preferred: Switch to LMWH (enoxaparin 1 mg/kg twice daily or 1.5 mg/kg once daily) if creatinine clearance ≥30 mL/min 3
• Alternative: Switch to warfarin with INR monitoring (target 2.0-3.0), as warfarin monitoring allows direct assessment of anticoagulant effect
• Warfarin is also affected by CYP induction but can be dose-adjusted based on INR

Key Caveats

• The trial data showing safety 2 likely included close monitoring that may not reflect routine practice
• No dose adjustment guidelines exist for apixaban when combined with strong CYP3A4/P-gp inducers
• The standard apixaban dose may be subtherapeutic when combined with apalutamide
• Cancer patients already have 4-7 fold increased VTE risk, making adequate anticoagulation critical

Common Pitfall to Avoid

Do not reflexively reduce apixaban dose thinking this is a drug interaction requiring dose adjustment like with inhibitors. The interaction with apalutamide goes in the opposite direction—it reduces apixaban levels, potentially requiring higher doses, not lower ones 1.

Bottom Line Recommendation

For VTE in cancer patients: Switch to LMWH, which is guideline-preferred for cancer-associated thrombosis and avoids this drug interaction entirely 3.

For atrial fibrillation: Either switch to warfarin with INR monitoring, or continue apixaban with intensive clinical surveillance for thrombotic events, recognizing that standard dosing may provide subtherapeutic anticoagulation.